晚期肺癌调强质子治疗必须进行自适应以确保靶区覆盖
结果显示,以95%CTV需被95%处方剂量覆盖为标准,61%患者需自适应,而光子治疗无患者需自适应。结论认为质子治疗需每日成像和自适应。
要点
- 61%的NSCLC患者接受质子治疗时需自适应以满足靶区覆盖。
- 光子治疗采用同一标准时无患者需自适应。
- 非刚性骨位置变化达15mm可导致靶区欠剂量。
核心结论
- 晚期肺癌质子治疗需每日成像和自适应以确保靶区覆盖。
研究设计与样本
- 自适应协议基于每日CBCT显示的靶区位置几何测量和大解剖变化。
- 治疗期间采集两次监测CT,通过重新计算质子计划评估解剖变化影响。
- 分析CTV接受95%处方剂量的覆盖情况。
主要发现
- 光子治疗采用同一标准时无患者需自适应。
- 自适应协议识别出6例质子治疗靶区严重欠剂量患者。
- 8例患者因非刚性变化(骨位置变化达15mm)出现靶区欠剂量。
关键数值与推荐
- 自适应需求判定标准:95%的CTV必须被95%的处方剂量覆盖。
- 非刚性骨位置变化达15mm与靶区欠剂量相关。
临床怎么用
- 晚期肺癌质子治疗应实施每日成像和治疗自适应。
- 需关注非刚性解剖变化(如骨位置变化达15mm)对靶区剂量的影响。
- 光子治疗的自适应决策支持协议可用于质子治疗但需调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Large anatomical changes during radiotherapy are seen for a large proportion of lung cancer patients. We investigate the applicability of a decision support protocol for photon therapy in a proton therapy setting. MATERIAL AND METHODS: Twenty-three consecutive NSCLC patients treated with adaptive photon therapy were retrospectively planned using IMPT. The adaptive protocol was based on geometrical measures of target positioning and large anatomical changes as shown on daily CBCT scans. Two surveillance CT-scans were acquired during the treatment course. The consequences of anatomical changes were evaluated by recalculating the proton plans on the surveillance scans. The CTV receiving 95% of the prescribed dose was analysed. RESULTS: Fourteen (61%) patients needed adaptations when treated with protons, given that 95% of the CTV must be covered by 95% of the dose. In comparison, no patients needed adaptation when treated with photons using this criterion. The adaptive protocol was found to identify patients with large target under-dosage for proton therapy (six patients). Additionally, target under-dosage was observed for eight patients with non-rigid changes up to 15mm in the positioning of the bones. CONCLUSIONS: Proton therapy for loco-regional lung cancer demands daily imaging and therapy adaptation for a high proportion of patients.
引用
- Hoffmann L, Alber M, Jensen MF, et al. Adaptation is mandatory for intensity modulated proton therapy of advanced lung cancer to ensure target coverage. Radiother Oncol. 2016. PMID: 28043645. doi:10.1016/j.radonc.2016.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。